Sanofi

The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Sanofi announced on June 30, 2022, that “the U.S. Food and Drug Administration (FDA) has placed Phase 3 studies of tolebrutinib in multiple sclerosis (MS) and myasthenia gravis on partial clinical hold.  As a result, new enrollment in the United States (U.S.) is paused, and participants in the U.S. who have been in the trial for fewer than 60 days shall suspend study drug.” The Company added, “[t]he FDA action was based on a limited number of cases of drug-induced liver injury that have been identified with tolebrutinib exposure in Phase 3 studies.” Based on this news, shares of Sanofi fell by more than 5% on the same day.

-->

Landsea Homes Corporation

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Landsea Homes Corporation (“Landsea” or “the Company”) (NASDAQ: LSEA) for violations of the securities laws.

-->

Abbott Laboratories

The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Abbott was the subject of testimony by Dr. Robert Califf, the head of the FDA, before the Energy and Commerce Subcommittee of the U.S. House of Representatives related to the ongoing baby formula shortage throughout the United States. According to the New York Times, Dr. Califf “detailed ‘egregiously unsanitary’ conditions” at the Company’s Michigan plant, which contributed to the shortage. Dr. Califf testified that “’the inspection results were shocking’” and that “’we had no confidence in integrity of the quality program at the facility.’”

-->

Clarivate Plc

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Clarivate Plc (“Clarivate” or “the Company”) (NYSE: CLVT) for violations of the securities laws.

-->

Nuvation Bio Inc.

The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Nuvation issued a press release on June 27, 2022, “announc[ing] the Food and Drug Administration (FDA) has placed a partial clinical hold on the Company’s Phase 1 dose escalation study of NUV-422 in solid tumors, including high grade glioma, HR+/HER2- advanced breast cancer and metastatic castration resistant prostate cancer.” According to the Company, “Following the emergence of uveitis, a form of inflammation in the eye, in certain patients receiving NUV-422, the Company proactively paused enrollment of new patients in order to further assess these adverse events with investigators and uveitis experts, and also reached out to the FDA for guidance around an appropriate path forward. While the partial hold is in place, no new patients will be enrolled in the NUV-422 program, although current study participants may continue to be treated in the Phase 1 study.” Based on this news, shares of Nuvation fell by more than 13% on the same day.

-->

Wells Fargo & Company

According to the Complaint, the Company made false and misleading statements to the market. Wells Fargo overstated its commitment to diverse hiring. The Company engaged in a scheme of faking candidate interviews to meet its “Diverse Search Requirement.” This scheme exposed the Company to risk of governmental action including potential criminal charges. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period. When the market learned the truth about Wells Fargo, investors suffered damages.

-->

The GEO Group, Inc.

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of The GEO Group, Inc. (“GEO” or “the Company”) (NYSE: GEO) for violations of the securities laws.

-->

Inotiv, Inc.

According to the Complaint, the Company made false and misleading statements to the market. The Cumberland, Virginia facility (the “Cumberland Facility”) of Inotiv and Envigo RMS, LLC (“Envigo”) suffered from common and extensive violations of the Animal Welfare Act (“AWA”). The Company’s Cumberland Facility violated the AWA on a continuous and ongoing basis. The Company failed to remedy the serious problems with animal welfare at the Cumberland Facility. The Company was likely to face governmental scrutiny and potential action over the AWA violations. The Company would subsequently shut down the Cumberland Facility. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period. When the market learned the truth about Inotiv, investors suffered damages.

-->

Generac Holdings Inc.

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Generac Holdings Inc. (“Generac” or “the Company”) (NYSE: GNRC)  for violations of the securities laws.

-->

MultiPlan Corporation

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of MultiPlan Corporation (“MultiPlan” or “the Company”) (NYSE: MPLN)  for violations of the securities laws.

-->